Proline-rich motifs are widely distributed in eukaryotic proteomes and are usually involved in the assembly of functional complexes through interaction with specific binding modules. The tumour -suppressor p53 protein presents a proline-rich region that is crucial for regulating apoptosis by connecting the p53 with a complex protein network. In humans, a common polymorphism determines the identity of residue 72, either proline or arginine, and affects the features of the motifs present in the polyproline domain. The two isoforms have different biochemical properties and markedly influence cancer onset and progression. In this article, we analyse the binding of the p53 proline-rich region with a pool of selected polyproline binding domains (i.e. SH3 and WW), and we present the first demonstration that the purified SH3 domains of the CD2AP/Cin85 protein family are able to directly bind the p53 protein, and to discriminate between the two polymorphic variants P72R.
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The p53 protein forms a homotetramer in most vertebrate species and also in some unicellular organisms, although not in yeast (1) . Since its discovery in 1979, countless papers have been published on the role of this crucial protein in both physiological and pathological conditions. Despite this vast amount of knowledge, many questions remain unanswered.
It was recently reported that the ancestral function of this conserved gene was not related to tumour development (1) . However, it later evolved as a genome guardian, showing evident tumour-suppressing activity. More than 35,000 mutations have been described in different cancers, many of which are somatic missense mutations with oncogenic functions (2, 3) . A common genetic polymorphism occurs at codon 72 of human p53 with two alleles encoding either a proline (P) or an arginine (R). Over the past decade, the two resulting variants have been extensively reported to influence cancer susceptibility, as well as other pathologies. Although the P allele is considered the ancient allele (the R variant has not been described in other primates (4)), the genotype frequencies in Europe are 60% R/R, 30% R/P and 10% P/P, suggesting that the R variant confers some advantages in this geographical background. By contrast, in African areas, the frequency of the P allele is higher (5, 6) . According to these observations, it has been hypothesized that UV radiation exposure or low average winter temperatures could influence the frequencies of the two variants (7, 8) .
A large number of genetic studies and meta-analyses have suggested an association of the polymorphism at codon 72 with the onset and/or the progression of tumours. In pioneering works, homozygous arginine was indicated as a risk factor in the HPV-associated tumourigenesis, because of the enhanced susceptibility of the protein to E6-mediated degradation (9, 10) . Other epidemiological studies have reported significantly lower or higher frequencies of R/R in non-HPV patients, depending on the subtype of cancer and on the ethnicity of the population analysed (1116). Moreover, the polymorphism has been reported to profoundly influence survival some years after cancer diagnosis, longevity and recurrent failure of in vitro fertilization (5, 17) . These epidemiological studies were supported by the findings that the polymorphism at codon 72 makes the two resulting p53 isoforms biologically different in terms of apoptotic potential (18, 19) under both normoxia and hypoxia (20, 21) , and differently able to induce cell senescence (22) . More recently, it has been reported that p53 can also interact with proteins involved in protection and replication of mitochondrial DNA (23, 24) . All these observations suggest that the substitution of a single amino acid in position 72 induces substantial changes in the biochemical properties of the protein. The region surrounding codon 72 is rich in proline residues, and it has been suggested to be an important signalling motif involved in the control of proliferation in a transcription-independent manner (2527). The region was shown to be required for suppressing tumour cell growth, and to promoting apoptosis in response to treatment with different chemotherapeutic agents (25, 27) . Notably, many species ranging from birds to mammals show a proline-rich stretch in the p53 protein; however, the number of PXXP motifs seems to increase during evolution and only in primates does the region contain five motifs, as in humans. These types of motifs have been shown in literature to adopt a distinct secondary structure called a poly-Lproline helix of type II, forming a unique recognition motif for protein interactions (28, 29) . They are frequently involved in signalling events by mediating the interaction with binding domains such as SH3 and WW domains (2932). The P72R polymorphism maps in the second PXXP repetition, and it has been described only in the human p53 sequence. Previous studies have demonstrated that the biological differences between the two p53 isoforms cannot be ascribed to changes in the secondary conformation introduced by the amino-acidic substitution at codon 72 (33) . We considered the possibility that the observed biological differences are due to differential capabilities of these amino acid motifs to bind p53 interactors. So far, few p53 interacting proteins have been shown to discriminate between the two polymorphic variants, and their binding specificity may indeed explain important aspects of the differential behaviour of the two isoforms (19, 3436) . Actually, the interaction was mapped in the proline region only for the SH3 domains of ASPP2 and iASPP, confirming that SH3 modules are involved in the regulation of the p53 network (19) . According to (19) , both proteins recognize two regions of the p53: the DNA-binding domain (DBD) domain (37) and the proline-rich region, but with different affinity, which gives rise to an interesting regulatory mechanism. In fact, iASPP, which inhibits the apoptotic function of p53 (38) , binds preferentially to the proline-rich region, with higher affinity for the P72 isoform, whereas ASPP2 that stimulates apoptosis (39) preferentially binds to the DBD. As a result, p53R escapes iASPP inhibition and is a better apoptosis inducer.
In this study, we have tested a collection of polyproline binding domains against the two isoforms of the p53 protein, to identify domains that could recognize the two polymorphic variants with different intensity. Exploiting protein domain arrays and a SPOT synthesis approach, we found evidence that the SH3 domains of the adaptor proteins CD2AP/Cin 85 are able to bind to this region. We showed that both the adaptors Cin85 and CD2AP bind to p53 in vitro and markedly prefer the R72 variant. Moreover, we mapped this interaction in the proline region of the p53. Finally, we showed that endogenous CD2AP form complexes with transfected p53 in H1299 cell lines.
Materials and Methods

Antibodies
Anti-GST was from GE-Healthcare, polyclonal and monoclonal antip53 were from Santa Cruz Biotechnology; Peroxidase-conjugated (POD) anti-rabbit and anti-mouse were from Jackson Immunoresearch, anti-goat was from SIGMA; anti-rabbit-Cy5 conjugated was from Jackson Immunoresearch and anti-mouse AlexaFluor555 was from Molecular Probes. Anti-Cin85 and anti-CD2AP were from Santa Cruz Biotechnology. Anti-Flag was from SIGMA.
Plasmids
The collection of domains used in the protein array experiment was previously collected in our lab (40) . The two p53 isoforms were amplified by PCR using a cDNA obtained from RT-PCR of total RNA from a heterozygous subject. The primers used were: 5_-CAC CATggAggAgCCgCAgTCAgAT-3_(For) and 5_-TCAgTCTg AgTCAggCCCTTC-3_ (Rev). The PCR products were cloned using pET151 directional TOPO expression kit (Invitrogen) as elsewhere described to obtain the expression plasmids (33) . CD2AP SH3 domains A, B and C were amplified from an H1299 cDNA library produced in our laboratory, and cloned in pGex2TK. Flag-Cin85 PCDNA and Cool1 beta Pix-SH3 were a generous gift from Prof. I. Dikic.
Cell cultures and transfection
Human embryonic kidney HEK293 cells and human lung carcinoma H1299 p53À/À cells were purchased from ATCC. Cells were maintained in a humidified atmosphere at 37 C and 5% CO 2 in Dulbecco's modified Eagle's medium (Invitrogen), supplemented with 10% fetal bovine serum (Sigma) and 0.1% penicillin/streptomycin (Invitrogen). Cells (5070% confluence) were transfected with Lipofectamine 2000 (Invitrogen) or with JetPEI (Polyplus) according to the manufacturer's protocol, and analysed 24 or 48 h posttransfection.
Construction of protein arrays and binding assay
A collection of 46 proline binding domains cloned in pGex vectors (40) were expressed in Escherichia coli BL21 Rosetta as glutathione-S-transferase (GST) fusion products. The proteins were purified by standard procedures with Glutathione Sepharose 4B (GE Healthcare) and eluted from the column with 10 mM glutathione. Their purity was assessed by electrophoresis. Proteins were dialyzed against phosphate-buffered saline (PBS) to remove glutathione and their concentration was estimated with Biorad assay. All the samples were brought to a final concentration of 1 mg/ml and arrayed in quadruplicate using a Microcaster Arrayer (Schleicher e Schuell). Each domain was arrayed twice on the same spot to increase the local concentration of the protein. They were spotted onto aldehyde-displaying glass slides to generate a rectangular array. In the first set of experiments, we arrayed 30 GST-fused domains to generate 2 grids of 4 lines and 32 columns each. Domains were spotted four times in two different lines to assess reproducibility of the binding (data not shown). In the second set of experiments, 46 domains were spotted in 2 grids of 6 lines and 32 columns and each domain was spotted four times (Fig. 1B ). Slides were air-dried in NaCl saturated atmosphere and one sample was tested with anti-GST to confirm domains binding.
The assay was performed incubating the slides in blocking solution (BSA 2% in PBS) for 30 min 4 C, then with the p53 protein. The slides were incubated with recombinant p53 expressed in E. coli BL21 Rosetta as histidine-tag fusion products and purified by standard procedure. After 2 h at 4 C arrays were washed three times in PBS and incubated with polyclonal anti-p53 (Santa Cruz) diluted 1:1,000 in BSA1% in PBS for 1 h 4 C. Alternatively they were incubated with monoclonal anti-p53 diluted 1:2,000 in the same solution. After three washing in PBS, the slides were incubated with anti-rabbit Cy5-conjugated or alternatively with anti-mouse Alexa-Fluor555 conjugated, in BSA 1% PBS. Signals were detected using a Fluorescence Microarray Scanner (ScanArray Gx Plus from PerkinElmer). For each spot, the software calculates the mean value of all pixel and subtracts the local background. These values were used in subsequent analyses, in which the mean of four spots of the same domain and the standard deviation were calculated (Supplementary Table S1 ).
Pull-down assay with recombinant p53 E. coli BL21 Rosetta expressing recombinant p53 P isoform or p53 R isoform with histidine tags were lysed by sonication. After centrifugation, extracts were quantified with Biorad assay and incubated for 
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SH3 domains of CD2AP bind to p53/72R isoform 2 h at 4 C with 50 mg of the selected GST-fused domain bound to glutathione sepharose beads. The resins were washed four times with 1 ml of PBS buffer 0.05% Tween, and the bound proteins were recovered by boiling in SDS-dye (50 mM Tris pH 6.8, 100 mM DTT, 2% SDS, 1% Bromophenol Blue, 10% glycerol), analysed by electrophoresis on a 10% SDS-polyacrylamide gel and blotted onto nitrocellulose membranes. The membranes were blocked for 2 h RT or overnight at 4 C in PBS containing 5% skimmed-milk powder (blocking solution), then incubated for 2 h at 4 C with polyclonal rabbit anti-p53 1:1,000 in blocking solution. After four washes in PBS 0.05% Tween, membranes were incubated with anti-rabbit POD conjugated for 45 min RT in blocking solution, and washed again four times in PBS 0.05% Tween. Bound p53 was revealed by chemiluminescence.
Pull-down assay with p53 expressed in mammalian cells Transiently transfected Hek293 or H1299 p53À/À cells were washed with PBS and collected by scraping in buffer containing 50 mM Tris pH7.4, 150 mM NaCl, 0.1% NP40, supplemented with protease inhibitors. After centrifugation, cell extracts were quantified with Biorad assay, and 500 mg of total extract was used in pull down experiments with GST-fused domains bound to sepharose beads. After 2 h 4 C the beads were washed repeatedly in 500 ml of the same buffer and the bound proteins were recovered by boiling in SDS-dye. They were analysed by electrophoresis, blotted onto nitrocellulose membranes, and p53 was revealed as described in the previous paragraph.
Immunoprecipitation assay
Transiently transfected H1299 p53À/À cells were washed with PBS and collected by scraping in buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 0.1% NP40, supplemented with protease inhibitors. The extracts were clarified by centrifugation, and protein concentration was determined by Bradford assay (Bio-Rad). Co-immunoprecipitations were performed on 500 micrograms/1milligram of protein extract, using the primary antibody for 4 h at 4 C, followed by A/G sepharose beads for 1 h at 4 C. For negative controls, sepharose beads with no antibodies were added. After three washes in the lysis buffer, samples were resolved on SDS-PAGE and elettroblotted on nitrocellulose membranes. Membranes were blocked in 5% skimmed milk, and then p53 was revealed with monoclonal antip53 followed by anti-mouse peroxidase conjugated. CD2AP and Cin85 were revealed with polyclonal specific antibodies followed by anti-rabbit POD conjugated.
Immunofluorescence H1299 cells were fixed with 4% of PFA for 5 min and blocked with PBS 1% Serum 10% TritonX-100, 1% for 1 h at RT. The cells were incubated with mouse anti-p53 (1:100 Santa Cruz), and rabbit anti-CD2AP (1:50 Santa Cruz) for 1 h at RT. After three washes, they were incubated with anti-mouse or anti-rabbit Alexa-Fluorconjugated (Invitrogen) diluted 1:250, 30 min at RT. The samples were washed three times and incubated with Hoescht (1 mg/ml, 5 min at RT), washed and mounted. Fluorescence images were acquired using Automated Microscope DMI 6000B Leica using 40Â objective. Confocal microscopy analysis was performed with Confocal Laser Scanning Microscope FV1000 Olympus using 60Â objective. Images were analysed with FV1000 Olympus Software. Pearson coefficients were obtained by generating manual region of interests covering the entire cell or selected regions of the cytoplasm.
Peptide arrays and binding assay
The peptide arrays were synthesized on cellulose-(3-amino-2-hydroxy-propyl)-ether. membranes (Intavis, Koeln, Germany). The peptides, 13-amino acid long, were synthesized according to standard spot synthesis protocols, using an automatic spot synthesizer (Intavis). Before use, the membranes were wet in ethanol and washed repeatedly in PBS.
The binding assay was performed incubating the membranes with 5 mg/ml of the GST-fused domain in blocking buffer overnight at 4 C. After washing three times for 10 min with PBS, the anti-GST antibody was added 1/1,000 in blocking buffer for 2 h at room temperature. After three washes with PBS (10 min each), POD-conjugated anti-goat mAb was added 1/5,000 in blocking buffer and incubated for 1 h at 4 C, followed by washing three times with PBS. Positive signals were revealed using a chemiluminescence substrate and the Las-3000 instrument (Fujifilm).
Results
Protein domain arrays reveal new p53 interactors
To identify polyproline binding domains that are able to discriminate between the p53 P and R isoforms, we performed protein array binding assays. The prolinerich region of the p53 protein in birds and mammals contains several PxxP motifs. This region is absent in invertebrates, suggesting that it has gained new functions during the course of evolution (Fig. 1A) . The polymorphism at codon 72 changes the second proline motif from PPVAP to PRVAP. We investigated whether any of the proline-rich binding domains involved in signal transduction could recognize this region and discriminate between the two motifs. SH3 and WW domains are well-known binders of prolinerich-motifs and are abundant in human cells. We chose a collection of 46 of these modules, spanning a large spectrum of recognition specificities (40) , produced them as GST fusions and arrayed them on activated glass slides, to generate domain chips. As previously described, while full length proteins are sometimes badly folded when expressed in heterologous systems and bound on glass slides, protein domains fused to GST usually retain their binding specificity (41) . Domains were purified from bacterial cultures and all the samples were brought to a final concentration of 1 mg/ml and spotted onto glass slides. GST alone was used as a negative control. A set of six identical arrays was generated to perform each experiment. The arrays were incubated with histidine-tagged p53, P72 or R72 isoforms, and the binding was revealed with anti-p53 antibody, followed by a fluorescent secondary antibody. Two arrays were incubated only with the antibodies to serve as a negative control. To highlight false interactions, two different anti-p53 antibodies were used to reveal the binding (Fig. 1B and C) . Domains that yielded higher reactions with both detection methods are reported in Fig. 1D . Interestingly, several WW and SH3 domains were shown to bind to both p53 isoforms; among them, the WW domains of Itch, Fbp21, Pin 1 and Gas7, and the SH3 domains of Argbp2 and Aspp2, which is a well-known p53 binding domain (37) . However, very few domains could consistently discriminate between the two polymorphic variants, and, among them, the SH3-C domain of Cin85 clearly preferred the p53R variant in all the experiments performed.
Identification of the binding region for SH3 domains on the p53 sequence To better characterize the positive interactions, we have utilized a different approach, which permits us to map the residues in the polyproline motif of p53 that bind the previously selected domains, if they recognize this region. We synthesized, on membrane support, an array of 14 peptides, 13-amino acids long, reproducing the p53 polyproline region surrounding codon 72. The membranes were probed with the GST-tagged domains that produced the strongest interactions in the previous experiment (Fig. 1D) , and the binding was revealed with anti-GST and secondary antibody conjugated to POD. No signal was detected with the WW domains of Itch, Fbp21, Pin1 or with Fbp11 and Wwox2, suggesting that no interaction occurred between these WW domains and the polyproline region under investigation, when T81 is unphosphorylated, in agreement with previous observations (42) (data not shown). On the contrary, the carbossiterminal SH3-C domain of Cin85 showed a strong binding with three of the p53 peptides, all containing the 67-PEAAPR-72 sequence (Fig. 2) . Cin85 is a broadly expressed multi-domain protein, which contains three SH3 domains, dubbed A, B and C (43) . Two homologues have been described in human and mouse cells: Cin85 and CD2-Associated Protein CD2AP (Fig. 3A) . It has been reported that the consensus binding motif for the SH3 domains of Cin85 is PXXXPR (44) . Two motifs matching this consensus are present in the p53 proline-rich: 60-PDEAPRM-66, which is present on both the isoforms, and 67-PEAAPR-72, which only occurs in the R variant. Our data clearly show that only the second motif was recognized by the SH3-C domain of Cin85.
We also tested the N-terminal SH3 domain of Cin85 that has the same binding specificity (44, 45) : as expected, we achieved the same result. In both cases, the binding was abolished if the first proline of the motif was deleted (Fig. 2) . To analyse the behaviour of the other member of the CMS/Cin85 family (Fig. 3A) , we cloned the three SH3 domains of CD2AP from a cDNA library of H1299 cells, and expressed them as GST fusion. The SH3-B domain of CD2AP showed a strong interaction with the same arginine-containing peptide of p53, as Cin85 (Fig. 2) .
Furthermore, the SH3 domain of Aspp2 and the second SH3 domain of ArgBP2 recognized the p53 polymorphic region. In agreement with previous observations (19, 40) , the SH3 of Aspp2 was able to recognize the polyproline peptides, both with P or R, with a preference for the R isoforms. The SH3-2 domain of ArgBP2 gave only a low signal with the peptide 69-AAPPVAPAPAAPTPA-83, while no signal was detected with the SH3-3 domain of the same protein.
GST alone was used as a negative control. The binding of Aspp2 with p53 has been already investigated (19) ; therefore, we focused on the SH3 domains of the CMS/Cin85 family.
Interaction of the CMS/Cin85 family members with the p53 isoforms
To further investigate the p53 binding to the family of Cin85/CD2AP, we performed a pull-down assay using recombinant p53 expressed in E. coli with a histidine tag, and GST-Cin85 SH3-C domain bound to glutathione sepharose beads. The binding was revealed with anti-p53, followed by incubation with a secondary antibody conjugated with POD. In agreement with the array and SPOT synthesis data, Cin85 SH3-C domain bound to the p53 protein with a strong preference for the R isoform. As shown in Fig. 4A , the first domain of Cin85 (SH3-A) presented the same behaviour. Notably, the SH3 domain of Cool-1 beta Pix, which recognized peptides containing PXXXPR motifs (46, 47) , did not bind to the p53R isoform, confirming that the interaction is specific. Bacterially expressed p53 presented several degradation bands, thus we next tested whether the SH3 domains of Cin85 could discriminate between p53 P and R isoforms when they were expressed in a more physiological system. To achieve this, we transfected human HEK 293 cells with p53P and p53R allelic variants and performed a pull-down assay with Cin85 SH3-A and Cin85 SH3-C. Both domains preferentially bound to the p53 R isoform (Fig. 4B) . Differential behaviour of the two isoforms has been reported to be cell-type specific (34) , thus, the same experiment was repeated in H1299 p53À/À cells, where the apoptotic potential of the R isoform has been investigated (34) . As shown in Fig. 4B , the results were identical.
The SH3-A and SH3-B of CD2AP were also able to bind bacterially expressed p53R in a pull-down assay, where the SH3-B gave a markedly stronger reaction (Fig. 3B) . Moreover, all three SH3 domains of CD2AP probed in the H1299 cell extract showed a preference for the R isoform. Once again, the SH3-B is the strongest p53 interactor (Fig. 3C ).
CD2AP proteins form in vivo complexes with cytoplasmic p53
To establish if p53 forms a complex in vivo with the CMS/ Cin85 proteins, we performed co-immunoprecipitation and co-localization analyses. We transiently expressed p53R and p53P in H1299 cells and analysed the co-immunoprecipitates with endogenous Cin85 and CD2AP. As shown in Fig. 5A , no specific association is revealed between endogenous Cin85 and p53. On the contrary, endogenous CD2AP co-immunoprecipitates with both the p53 isoforms, but it shows a marked preference for the p53R isoform (Fig. 5A) . Furthermore, although overexpressed, Cin85 does not recognize p53 (Fig. 5C) . Thus, we conclude that in the H1299 environment, in unstressed and unstimulated conditions, a fraction of p53 is in complex with CD2AP but not with Cin85. In addition, the p53 R isoform is a better ligand for CD2AP.
To assess the p53 co-localization with CD2AP, we performed immunofluorescence staining of the endogenous CD2AP and transfected p53P or p53R. In agreement with previous reports, CD2AP showed a diffused distribution with a slight accumulation in the cytosolic perinuclear regions (48) . Localization of over-expressed p53 is mainly nuclear in H1299 cells, but, in some cells, it was also localized in the cytosol. As shown in Fig. 6 , the cytosolic form of p53 colocalized with CD2AP. Cytosolic localization of the p53 protein was not unexpected; it has been reported that the protein underwent nuclear-cytoplasmic shuttling in unstressed cells, whereas it is mainly nuclear in immortalized cells (4954). The co-localization was confirmed by confocal microscopy. In Fig. 6B , p53 and CD2AP co-localized in merge panels. The localization was analysed with Olimpo FV1000 software in the selected cytosolic areas (inset circles).
SH3 domains of CD2AP bind to p53/72R isoform
As shown, both isoforms are co-localized with CD2AP, with a little increase for the p53 R form (Pearson coefficients 0.81 and 0.84 for P and R, respectively).
Discussion
The p53 protein is a crucial node for the regulation of cell physiology. Although it mainly functions as 2 Cin85 and CD2AP SH3 domains bind to the proline-rich of the p53 R isoform. Arrays of 14 peptides, 13-amino acid long, matching the sequence of p53 polyproline region and surrounding the codon 72 were synthesized and incubated with SH3 domains as indicated. Peptides indicated with con are control peptides that bind to GST alone. Peptides 3P to 8R contain, in the position in bold, the 72nd residue, either a proline (P lane) or an arginine (R lane). The binding was revealed with anti-GST followed by a secondary antibody bound to POD. All experiments were repeated at least twice.
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transcriptional activator, distinct roles for this protein have been proposed since 1994 (5557). In particular, the proline-rich region of the human p53 has been shown to be dispensable for modulating transcription, while playing an essential role in other functions of the protein (25, 27) . Clearly, the P72R polymorphism markedly influences the protein's performance in normal and tumour cells; as such, it has been investigated since it interferes with the ability of p53 to interact with other proteins. Actually, the apoptosis inhibitor iAspp was shown to discriminate between the two polymorphic variants, and to prefer the 
SH3 domains of CD2AP bind to p53/72R isoform
P72p53, whereas the R72 isoform can exert its higher apoptotic potential (19) . Other interesting molecular models have been proposed to explain the different behaviour of the two isoforms (3436); however, further investigations are needed to address the extent to which the diverse and complex characteristics of the polymorphic variants are integrated in contributing to the final phenotypes. Contradictory results have been obtained with mouse models: some reports concluded that the characteristics of the polymorphic variants are species-specific and not reproducible in mouse models (58) , while other studies have demonstrated that mouse cells reproduce human results (36, 59) . Notably, most studies pointed out that the effect of the polymorphism correlated to cell type, which may be the result of the presence in different tissues of different protein interactors and different expression levels of ubiquitous interactors.
Having excluded the possibility that the difference in biological activity of the two isoforms may be because of the modifications in the secondary structure induced by the P72R polymorphism (33), it is plausible that such a difference may be accounted for a diverse subcellular localization of the two isoforms that in turn can be due to a preferential interaction with other factors. In particular, it has been reported that the R isoform is retained at cytoplasmic level more than the P isoform (34) .
In agreement with this hypothesis, in this article, we identified CD2AP, which is a ubiquitously expressed adaptor protein with three SH3 domains (43) , as a novel binding protein of cytosolic p53. All three SH3 domains of CD2AP were able to bind to p53 and the second SH3 is the strongest binder, specifically with the p53R isoform. CD2AP has multiple, tissue-specific functions. In T-cells, it has been shown to interact with the cell adhesion molecule CD2 to assist CD2 in clustering and cytoskeletal polarization during antigen recognition, whereas CD2AP-deficient mice showed impaired T-cell function, but died of renal failure (60, 61) . More recently, it has been reported that CD2AP is involved in actin remodelling and, similarly to Cin85, in the endocytic degradative pathway of receptors (6264). By virtue of its ability to connect different partner proteins, CD2AP may anchor p53, and in particular the R isoform, in the cytosol. In fact, in non-immortalized and unstressed cells, the p53 is exported to the cytosol where it is rapidly polyubiquitinated and degraded (53, 54, 65) . However, it has been shown (57) that a part of the cytosolic pool of p53 undergoes monoubiquitination instead of degradation, and, upon genotoxic stress, is imported into mitochondria where it exerts its pro-apoptotic function.
Mechanisms that regulate the balance between stable, monoubiquitinated and polyubiquitinated p53 are numerous and not completely defined (57) . Binding to CD2AP may partially protect the p53 from polyubiquitination and degradation. A similar model had been proposed in the past for several cytoplasmic proteins to explain cytosolic localization of the p53, as reviewed in (52) . Particularly in neuroblastoma cells, the PARC protein has been shown to sequester the p53 in the cytoplasm, inhibiting it (66) . According to our data, CD2AP preferential interaction with the p53R isoform may allow sequestration of a higher fraction of p53R out of the nucleus, in accordance with the observation that p53R preferentially migrates to mitochondria in response to apoptotic stimuli (34) . Interestingly, the SH3 domains of CD2AP were shown to bind to monoubiquitin moieties, which could reinforce the binding to ubiquitinated p53 (67) .
CD2AP directly interacts with both actin and membrane proteins, and it has been proposed as a link between receptors or other membrane proteins (such as nephrin) and the actin cytoskeleton (64, 68) . According to our observations, it may also link receptors to the p53 protein. In fact, several reports reveal cross-talking between the cytoplasmic p53 protein and different growth factor receptors, as well as cytokines and Fas receptors (35, 55, 6971) . In particular, in response to EGF treatment, a cytosolic fraction of p53 was shown to form a complex with clathrin at the plasma membrane in normal and cancer human cells, and to influence EGFR endocytosis (69, 71) . Moreover, mutant forms of p53 promote plasma membrane localization Fig. 6 Colocalization of cytoplasmic p53 with CD2AP. H1299 cells were grown on coverslip and transiently transfected with p53 P or R respectively. Twenty four hours after transfection cells were fixed and the p53 protein was stained with monoclonal anti-p53 followed by anti-mouse, while endogenous CD2AP was stained with anti-CD2AP followed by anti-rabbit. (A) The immunofluorescence was visualized with automated fluorescence microscopy. (B) Co-localization of p53 with CD2AP was confirmed by confocal microscopy. The staining in the first two columns corresponds to transfected p53, P or R as indicated, and to endogenous CD2AP. The staining in merge panels indicates the presence of both proteins. The inset boxes highlight the areas analysed with Olympus AV1000 software. Pearson coefficients were obtained by generating manual ROIs. (Inset circles). Pearson:0,81 and 0,84 respectively for P and R.
of EGFR and integrins (72) . We did not observe interaction with Cin85 full-length protein, in vivo, even upon induction with EGFR. However, we cannot exclude the possibility that the two proteins might bind in different physiological environments.
CD2AP was shown to regulate the formation and maintenance of cellcell interaction via Rac 1 (73) and to directly bind F-actin to modulate cytoskeleton rearrangements (74) . Notably, p53 also cooperates with Rac1 in the control of cell proliferation and migration, in normal and invasive cells (75, 76) . In p53À/À lymphoma cells, Rac1 deletion was able to abrogate hyperproliferation and to induce apoptosis (76) . Clearly, the complicated connections between p53 and CD2AP signalling pathways require further study to address the physiological significance of their binding, and to clarify the real capability of the P72R polymorphism to influence the cytosolic functions of the p53 protein.
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